Summary

The global Favipiravir Tablets market size was US$ 23.5 million in 2024 and is forecast to a readjusted size of US$ 5.3 million by 2031 with a CAGR of -22.6% during the forecast period 2025-2031.
Favipiravir tablets are an oral antiviral medication primarily developed to treat influenza and other RNA virus infections. They function by inhibiting the RNA-dependent RNA polymerase enzyme, thereby preventing the replication of viral RNA. Favipiravir tablets have been explored as a treatment option for various emerging viral diseases, including COVID-19, due to their broad-spectrum antiviral activity. The tablet form offers convenient administration, making it suitable for outpatient use and large-scale public health responses.

The market for Favipiravir tablets has experienced significant attention due to their potential role in managing viral outbreaks, especially during the COVID-19 pandemic. As an orally administered antiviral with broad-spectrum activity against RNA viruses, Favipiravir tablets offer an accessible treatment option, especially in outpatient and home settings. The convenience of oral dosage makes them ideal for large-scale use during pandemics, particularly in countries with limited hospital infrastructure. Governments and healthcare organizations have incorporated Favipiravir tablets into emergency stockpiles and treatment protocols, boosting their demand. Additionally, ongoing research on their effectiveness in treating other viral diseases such as Ebola, Lassa fever, and hemorrhagic fevers supports future use cases. The global emphasis on pandemic preparedness and demand for scalable, shelf-stable antivirals continues to be a major market driver.

Despite its advantages, the Favipiravir tablets market faces several challenges that affect its long-term sustainability. The clinical efficacy of Favipiravir, particularly for COVID-19 and other non-influenza viral infections, has shown inconsistent results in global trials, leading to divided opinions among regulatory bodies. Its teratogenic risks restrict use in certain populations, including pregnant women, limiting widespread application. The presence of newer antivirals with stronger clinical backing—like molnupiravir and nirmatrelvir/ritonavir (Paxlovid)—creates stiff competition in both developed and emerging markets. Moreover, intellectual property concerns, varying manufacturing standards, and price fluctuations across regions may create regulatory and distributional barriers. Without further clinical validation and innovation in formulation or combination therapies, Favipiravir tablets risk losing market relevance.

The global Favipiravir Tablets market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
By 2025, the evolving U.S. tariff policy is poised to inject considerable uncertainty into the global economic landscape. This report delves into the latest U.S. tariff measures and the corresponding policy responses across the globe, evaluating their impacts on Favipiravir Tablets market competitiveness, regional economic performance, and supply chain configurations.

Market Segmentation
By Company:
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm
By Type: (Dominant Segment vs High-Margin Innovation)
Brand Drug
Generic Drug
By Application: (Core Demand Driver vs Emerging Opportunity)
Influenza Viruses
COVID-19
Others
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., ChemRar Group in Europe)
- Emerging Product Trends: Brand Drug adoption vs. Generic Drug premiumization
- Demand-Side Dynamics: Influenza Viruses growth in China vs. COVID-19 potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)

Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Favipiravir Tablets market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Generic Drug in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., COVID-19 in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Brand Drug dominance in Europe vs. Generic Drug demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Favipiravir Tablets Product Scope
1.2 Favipiravir Tablets by Type
1.2.1 Global Favipiravir Tablets Sales by Type (2020 & 2024 & 2031)
1.2.2 Brand Drug
1.2.3 Generic Drug
1.3 Favipiravir Tablets by Application
1.3.1 Global Favipiravir Tablets Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Influenza Viruses
1.3.3 COVID-19
1.3.4 Others
1.4 Global Favipiravir Tablets Market Estimates and Forecasts (2020-2031)
1.4.1 Global Favipiravir Tablets Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Favipiravir Tablets Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Favipiravir Tablets Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Favipiravir Tablets Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Favipiravir Tablets Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Favipiravir Tablets Sales Market Share by Region (2020-2025)
2.2.2 Global Favipiravir Tablets Revenue Market Share by Region (2020-2025)
2.3 Global Favipiravir Tablets Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Favipiravir Tablets Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Favipiravir Tablets Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Favipiravir Tablets Market Size and Prospective (2020-2031)
2.4.2 Europe Favipiravir Tablets Market Size and Prospective (2020-2031)
2.4.3 China Favipiravir Tablets Market Size and Prospective (2020-2031)
2.4.4 Japan Favipiravir Tablets Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Favipiravir Tablets Historic Market Review by Type (2020-2025)
3.1.1 Global Favipiravir Tablets Sales by Type (2020-2025)
3.1.2 Global Favipiravir Tablets Revenue by Type (2020-2025)
3.1.3 Global Favipiravir Tablets Price by Type (2020-2025)
3.2 Global Favipiravir Tablets Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Favipiravir Tablets Sales Forecast by Type (2026-2031)
3.2.2 Global Favipiravir Tablets Revenue Forecast by Type (2026-2031)
3.2.3 Global Favipiravir Tablets Price Forecast by Type (2026-2031)
3.3 Different Types Favipiravir Tablets Representative Players
4 Global Market Size by Application
4.1 Global Favipiravir Tablets Historic Market Review by Application (2020-2025)
4.1.1 Global Favipiravir Tablets Sales by Application (2020-2025)
4.1.2 Global Favipiravir Tablets Revenue by Application (2020-2025)
4.1.3 Global Favipiravir Tablets Price by Application (2020-2025)
4.2 Global Favipiravir Tablets Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Favipiravir Tablets Sales Forecast by Application (2026-2031)
4.2.2 Global Favipiravir Tablets Revenue Forecast by Application (2026-2031)
4.2.3 Global Favipiravir Tablets Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Favipiravir Tablets Application
5 Competition Landscape by Players
5.1 Global Favipiravir Tablets Sales by Players (2020-2025)
5.2 Global Top Favipiravir Tablets Players by Revenue (2020-2025)
5.3 Global Favipiravir Tablets Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Favipiravir Tablets as of 2024)
5.4 Global Favipiravir Tablets Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Favipiravir Tablets, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Favipiravir Tablets, Product Type & Application
5.7 Global Key Manufacturers of Favipiravir Tablets, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Favipiravir Tablets Sales by Company
6.1.1.1 North America Favipiravir Tablets Sales by Company (2020-2025)
6.1.1.2 North America Favipiravir Tablets Revenue by Company (2020-2025)
6.1.2 North America Favipiravir Tablets Sales Breakdown by Type (2020-2025)
6.1.3 North America Favipiravir Tablets Sales Breakdown by Application (2020-2025)
6.1.4 North America Favipiravir Tablets Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Favipiravir Tablets Sales by Company
6.2.1.1 Europe Favipiravir Tablets Sales by Company (2020-2025)
6.2.1.2 Europe Favipiravir Tablets Revenue by Company (2020-2025)
6.2.2 Europe Favipiravir Tablets Sales Breakdown by Type (2020-2025)
6.2.3 Europe Favipiravir Tablets Sales Breakdown by Application (2020-2025)
6.2.4 Europe Favipiravir Tablets Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Favipiravir Tablets Sales by Company
6.3.1.1 China Favipiravir Tablets Sales by Company (2020-2025)
6.3.1.2 China Favipiravir Tablets Revenue by Company (2020-2025)
6.3.2 China Favipiravir Tablets Sales Breakdown by Type (2020-2025)
6.3.3 China Favipiravir Tablets Sales Breakdown by Application (2020-2025)
6.3.4 China Favipiravir Tablets Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Favipiravir Tablets Sales by Company
6.4.1.1 Japan Favipiravir Tablets Sales by Company (2020-2025)
6.4.1.2 Japan Favipiravir Tablets Revenue by Company (2020-2025)
6.4.2 Japan Favipiravir Tablets Sales Breakdown by Type (2020-2025)
6.4.3 Japan Favipiravir Tablets Sales Breakdown by Application (2020-2025)
6.4.4 Japan Favipiravir Tablets Major Customer
6.4.5 Japan Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 ChemRar Group
7.1.1 ChemRar Group Company Information
7.1.2 ChemRar Group Business Overview
7.1.3 ChemRar Group Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.1.4 ChemRar Group Favipiravir Tablets Products Offered
7.1.5 ChemRar Group Recent Development
7.2 Glenmark
7.2.1 Glenmark Company Information
7.2.2 Glenmark Business Overview
7.2.3 Glenmark Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Glenmark Favipiravir Tablets Products Offered
7.2.5 Glenmark Recent Development
7.3 Fujifilm
7.3.1 Fujifilm Company Information
7.3.2 Fujifilm Business Overview
7.3.3 Fujifilm Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Fujifilm Favipiravir Tablets Products Offered
7.3.5 Fujifilm Recent Development
7.4 Dr. Reddy
7.4.1 Dr. Reddy Company Information
7.4.2 Dr. Reddy Business Overview
7.4.3 Dr. Reddy Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Dr. Reddy Favipiravir Tablets Products Offered
7.4.5 Dr. Reddy Recent Development
7.5 R-Pharma
7.5.1 R-Pharma Company Information
7.5.2 R-Pharma Business Overview
7.5.3 R-Pharma Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.5.4 R-Pharma Favipiravir Tablets Products Offered
7.5.5 R-Pharma Recent Development
7.6 Cipla
7.6.1 Cipla Company Information
7.6.2 Cipla Business Overview
7.6.3 Cipla Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Cipla Favipiravir Tablets Products Offered
7.6.5 Cipla Recent Development
7.7 Lupin
7.7.1 Lupin Company Information
7.7.2 Lupin Business Overview
7.7.3 Lupin Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Lupin Favipiravir Tablets Products Offered
7.7.5 Lupin Recent Development
7.8 Sun Pharma
7.8.1 Sun Pharma Company Information
7.8.2 Sun Pharma Business Overview
7.8.3 Sun Pharma Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Sun Pharma Favipiravir Tablets Products Offered
7.8.5 Sun Pharma Recent Development
7.9 Hisun Pharm
7.9.1 Hisun Pharm Company Information
7.9.2 Hisun Pharm Business Overview
7.9.3 Hisun Pharm Favipiravir Tablets Sales, Revenue and Gross Margin (2020-2025)
7.9.4 Hisun Pharm Favipiravir Tablets Products Offered
7.9.5 Hisun Pharm Recent Development
8 Favipiravir Tablets Manufacturing Cost Analysis
8.1 Favipiravir Tablets Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Favipiravir Tablets
8.4 Favipiravir Tablets Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Favipiravir Tablets Distributors List
9.3 Favipiravir Tablets Customers
10 Favipiravir Tablets Market Dynamics
10.1 Favipiravir Tablets Industry Trends
10.2 Favipiravir Tablets Market Drivers
10.3 Favipiravir Tablets Market Challenges
10.4 Favipiravir Tablets Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer